Vascular proliferation and mononuclear cell infiltration are prominent changes observed in synovium from actively inflamed joints of patients with rheumatoid arthritis. Angiotensin converting enzyme (ACE) is a halide activated peptidase produced mainly by endothelial cells and by activated monocytes. It has been proposed that levels of ACE activity in synovial fluid might reflect changes in membrane vascularity, the degree of monocyte infiltration, or the thickness of the lining layer. In this study, ACE activity in serum and synovial fluid samples from 18
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Vascular proliferation and mononuclear cell infiltration are prominent changes observed in synovium from actively inflamed joints of patients with rheumatoid arthritis. Angiotensin converting enzyme (ACE) is a halide activated peptidase produced mainly by endothelial cells and by activated monocytes. It has been proposed that levels of ACE activity in synovial fluid might reflect changes in membrane vascularity, the degree of monocyte infiltration, or the thickness of the lining layer. In this study, ACE activity in serum and synovial fluid samples from 18 patients with inflammatory arthritis was measured and compared with levels in 12 control subjects with non-inflammatory arthritis. Although serum levels were similar in the two groups, ACE activity in synovial fluid was significantly increased in the group with inflammatory arthritis compared with controls (mean (SE) 37 (5) (3) ). Staining of synovial membranes from patients with rheumatoid arthritis with a monoclonal antibody to ACE localised ACE to the endothelium and to mononuclear cells of macrophage origin. ACE activity was then measured in supernatants of synovial membrane from patients with rheumatoid arthritis after one and seven days of culture. A significant increase in ACE activity was observed after seven days of culture (mean (SE) day 1, 17 (5) v day 7, 25 (3) ). Levels In a further study, however, the number of vessels and vascular morphology in synovial membrane obtained from patients with rheumatoid arthritis, by needle biopsy and at arthroplasty, were examined and no difference between those with early or late disease was observed.5 It has been suggested that some of the disease modifying antirheumatic drugs may act by inhibiting macrophage function or by reducing vascular proliferation."8 Thus it would be of interest to examine the effects of treatment with these drugs on the histological features of synovial membrane.
As the repeated taking of synovial biopsy samples might prove unacceptable for many patients, a readily detectable marker ofmonocyte function and vascularity in synovial fluid samples would be useful. Angiotensin converting enzyme (ACE) produced mainly by endothelial cells9 and by activated monocytes,10 might be such a marker. In this study, ACE activity was measured in serum and synovial fluid samples obtained from patients with inflammatory and non-inflammatory joint disease. The localisation of ACE in synovial membranes from patients with rheumatoid arthritis was also examined using a monoclonal antibody to ACE. ACE activity was also measured in the synovial fluid of patients with rheumatoid arthritis undergoing arthroplasty and in the supernatants derived from their synovial membrane cultures. Levels of ACE activity in the synovial fluid and in the supernatants were correlated with the immunohistological features of the synovial membrane and with interleukin 1 and interleukin 6 production in the synovial membrane.
Materials and methods

PATIENTS
Concomitant samples of serum and synovial fluid were taken from the knees of patients with inflammatory arthritis and from patients with non-inflammatory knee effusions. The group with inflammatory arthritis included patients with rheumatoid arthritis, as defined by the revised American College of Rheumatology criteria,"1 reactive arthritis, seronegative rheumatoid arthritis, gout, and systemic lupus erythematosus. The group with non-inflammatory arthritis was composed of patients with osteoarthritis and patients undergoing arthroscopy for traumatic knee injury. In the second part of the study, synovial fluid and synovium samples were obtained at arthroplasty from a further group ofpatients with seropositive rheumatoid arthritis.
Blood and synovial fluid samples were taken in plain tubes and centrifuged. All samples of serum and centrifuged synovial fluid were then stored at -20°C until analysed. Blood samples were also analysed for haemoglobin, erythrocyte sedimentation rate (Westergren), and rheumatoid factor (latex fixation).
SYNOVIAL MEMBRANE CULTURES
Undigested synovial membrane (0-25 g), dissected free of tendinous and adipose tissue, was cultured in 1-25 ml of RPMI (Gibco, Paisley, UK) containing 10% fetal calf serum (Panox, Antrim, UK), 1% glutamine (Gibco), 1-8 ,ug/ml amphotericin, and 50 ,ug/ml gentamicin (Gibco) in sterile flat bottomed multiwell tissue culture plates. Following incubation at 37°C in a humidified atmosphere with 5% CO2, the tissue supernatants were harvested at days 1 and 7 for the determination ofcytokines and ACE activity.
Interleukin 1 and ipterleukin 6 in the two groups were receiving a variety of non-steroidal anti-inflammatory drugs and six of the patients with rheumatoid arthritis were also receiving disease modifying drugs. No patients had received intra-articular corticosteroids within three months of the study.
ACE IN SERUM AND SYNOVIAL FLUID
Although serum ACE levels tended to be higher in the group with inflammatory arthritis compared with the controls, no statistically significant difference was observed. In contrast, the mean (SE) ACE activity (U/ml) in the synovial fluid of the group with inflammatory arthritis was 37 (5) which was significantly greater than that in the group with non-inflammatory arthritis (19 (3); p<005) (fig 1) . In addition, 10 antibody to ACE and the CD 14 monocyte marker.
SYNOVIAL MEMBRANE CULTURES
The mean (SE) ACE activity in the synovial fluid samples taken at arthroplasty from 12 patients with rheumatoid arthritis was 38 (6). The ACE activity in the synovial membrane culture supernatants at day 1 was 17 (5) and at day 7 showed a significant increase to 25 (3) (p=005) (fig 3) . A significant correlation was observed between the ACE activity in synovial fluid and the increase in ACE activity from days 1 to 7 (p=0-001). Levels of ACE activity at days 1 and 7 showed a significant correlation (p= 0o001).
As ACE is a product of endothelial cells and activated macrophages, attempts were made to correlate ACE activity in the synovial fluid or synovial membrane supernatants with membrane vascularity or macrophage number. No such correlation was observed. The ACE activity did not correlate either with numbers of T cells, T cell subsets, B cells, lining layer thickness, or synovial membrane supernatant levels of interleukin 1 or interleukin 6.
Discussion
Angiotensin converting enzyme is a halide activated peptidase which catalyses the releaise of histidylleucine from the COOH terminus of the decapeptide angiotensin I to yield a pressor peptide, angiotensin II.9 In addition, ACE inactivates bradykinin, an important vasodilator, by catalysing the sequential release of phenylalanine-arginine and serine-proline from the COOH terminus.'5 Bradykinin has been shown to be present in synovial fluid in inflammatory arthritis,'6 to have proinflammatory effects on fibroblasts,'7 and also leads to stimulation of pain fibres. '8 27 In one study, although serum levels were similar in patients with rheumatoid arthritis, osteoarthritis, seronegative arthropathy, and in normal controls, synovial fluid ACE activity was higher in patients with rheumatoid arthritis than in those with osteoarthritis, though they were similar when corrected for protein levels.26
More recently, ACE activity was assayed in serum free conditioned medium from unstimulated peripheral blood monocytes from patients with rheumatoid arthritis, osteoarthritis, and from normal controls. 27 The results indicate that monocytes from patients with rheumatoid arthritis, in particular those with early disease, produce more ACE than monocytes from control subjects. That study did not examine the production of ACE by synovial monocytes This is the first study to show the de novo production of ACE in the synovial membrane of patients with rheumatoid arthritis and the localisation of the enzyme to the endothelium and to monocytes. The potential part played by ACE in the inflamed synovial membrane is uncertain, but by increasing the conversion of angiotensin I to angiotensin II and by inactivating bradykinin, ACE would predominantly have a vasopressor effect. This might in turn lead to episodes of tissue hypoxia, which when followed by reperfusion may lead to a release of oxygen free radicals, thought to be important mediators of cell damage in rheumatoid arthritis.28
